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Abstract
Objective—The increased use of opioids to treat chronic pain in the past 20 years has led to a 
drastic increase in opioid prescribing in the United States. The CDC Guideline for Prescribing 
Opioids for Chronic Pain recommends the use of nonopioid therapy as the preferred treatment for 
chronic pain. This study analyzes the prevalence of nonopioid prescribing among commercially-
insured patients with chronic pain.
Design—Data from the 2014 MarketScan database representing claims for commercially-insured 
patients were used. International Classification of Diseases, Ninth Revision (ICD-9-CM) codes 
were used to identify patients with chronic pain. Nonopioid prescriptions included nonsteroidal 
anti-inflammatory drugs (NSAIDs), analgesics/antipyretics (e.g. acetaminophen), anticonvulsants, 
and antidepressant medications. The prevalence of nonopioid and opioid prescriptions were 
calculated by age, sex, insurance plan type, presence of a depressive or seizure disorder, and 
region.
Results—In 2014, among patients with chronic pain, 16% filled only an opioid, 17% filled only 
a nonopioid prescription, and 28% filled both a nonopioid and an opioid. NSAIDs and 
antidepressants were the most commonly prescribed nonopioids among patients with chronic pain. 
Having prescriptions for only nonopioids was more common among patients aged 50–64 years 
and female patients.
Conclusions—This study provides a baseline snapshot of nonopioid prescriptions prior to the 
release of the CDC Guideline and can be used to examine the impact of the CDC Guideline and 
other evidence-based guidelines on nonopioid use among commercially-insured patients with 
chronic pain.
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INTRODUCTION
Millions of adults are affected by chronic noncancer pain in the United States. Although the 
majority of chronic noncancer pain patients receive care in the primary care setting,(1) 
primary care providers have reported being inadequately prepared to manage chronic pain.
(2) Over the past two decades, chronic noncancer pain was increasingly treated with 
prescription opioids,(3) while previously, opioids had primarily been reserved for severe 
acute pain, postsurgical pain, and end-of-life care. As a result, opioid prescribing increased 
dramatically in the United States and remains high with considerable variation across the 
country.(4)
In parallel with the dramatic increase in prescription opioid use, drug overdose deaths 
involving opioids have increased substantially in the United States.(5) In 2016, in response 
to the increased harms from prescription opioids and as part of efforts to better equip 
clinicians with evidence-based tools to ensure patient safety, the Centers for Disease Control 
and Prevention (CDC) released the Guideline for Prescribing Opioids for Chronic Pain.(6) 
Of note, the CDC Guideline recommends the use of nonopioid therapy for the treatment of 
chronic noncancer pain. Nonopioid therapy includes nonopioid pharmacologic options, such 
as ibuprofen, and nonpharmacologic methods of managing pain, like exercise and cognitive 
behavioral therapy. It is unclear how commonly nonopioids are prescribed for patients with 
chronic noncancer pain. The purpose of this study is to examine the prevalence of nonopioid 
prescriptions among commercially insured chronic noncancer pain patients (herein defined 
as patients with chronic pain).
METHODS
This cross-sectional analysis used the 2014 Truven Health MarketScan Research 
commercial claims and encounters Databases for the commercially insured population. The 
database is one of the largest administrative databases of commercially insured individuals 
and includes de-identified enrollee-level utilization, expenditures, and enrollment 
information across outpatient and inpatient visits and prescription drugs.(7) Data on patient 
age, sex, insurance plan type, prescription drug coverage, and region were collected from the 
enrollment files. International Classification of Diseases, Ninth Revision, Clinical 
Modification (ICD-9-CM) codes were used to identify patients with chronic pain, depressive 
disorders, and seizure disorders (Appendix A). Patients with at least two outpatient visits at 
least 90 days apart linked to the same chronic pain condition ICD-9-CM code were 
considered patients with chronic pain. The study period consisted of 12 months from 
January 1, 2014 to December 31, 2014, with a 3 month pre period from October 1, 2013 to 
December 31, 2013 and a 3 month post period from January 1, 2015 to March 31, 2015. 
Data on prescription drugs was collected from the 12 month study period, while 
identification of chronic pain conditions utilized the full 18 months to ensure that we were 
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able to identify all chronic pain patients in 2014. Patients were excluded from the analysis if 
they were not continuously enrolled during the 12 month study period, did not have 
prescription drug coverage, or were over the age of 65 years as this is the eligibility age for 
Medicare.
Filled opioid and nonopioid prescriptions were identified using the National Drug Code 
schema (Appendix B). Nonopioid prescriptions included those for nonsteroidal anti-
inflammatory drugs (NSAIDs), analgesics/antipyretics (e.g. acetaminophen), and certain 
medications in the anticonvulsant and antidepressant classes which are sometimes also used 
to treat pain.1 Chi-square analysis was used to compare characteristics of patients with 
chronic pain to patients without chronic pain. Prevalence of nonopioid prescriptions (total 
and by class); opioid prescriptions; and prescriptions for both nonopioids and opioids were 
calculated by age, sex, insurance plan type, presence of a depressive disorder diagnosis, 
presence of a seizure disorder diagnosis, and US Census region.
RESULTS
The study population included 21,745,233 patients, of which 9.5% had chronic pain during 
the study period. Patients with chronic pain were more likely to be aged ≥30 years and 
female compared to those without a chronic pain condition (Table 1). Among patients with 
chronic pain, 38.3% had filled no prescriptions; however 28.4% had a prescription for an 
opioid and a nonopioid, 17.4% had only a nonopioid prescription, and 15.9% had only an 
opioid prescription. Both opioid and nonopioid prescriptions, individually and in 
combination, were more common among patients with chronic pain compared to patients 
without a chronic pain diagnosis (all p<0.001).
Among patients with chronic pain, nonopioid prescriptions increased with age and were 
more common among female patients than male patients, and among patients in a Health 
Maintenance Organization (19.8%) or in a point of service with capitation (18.6%; Table 2). 
Patients with chronic pain in the Northeast were the most likely to fill nonopioid 
prescriptions only (19.3%), while those in the West were least likely (14.9%). Among 
patients with chronic pain and a co-occurring depressive disorder, 19.0% filled only 
nonopioids, while 44.9% had prescriptions for both opioids and a nonopioid, and 14.3% 
only filled a prescription for an opioid.
Among the filled nonopioid prescriptions of patients with chronic pain, NSAIDS were the 
most common (74.8%) followed by antidepressants (26.7%), and then anticonvulsants 
(25.9%) (Table 3). NSAIDs were more common among males, while antidepressants were 
more common among females.
DISCUSSION
This study found that prescriptions for both opioids and nonopioids were common among 
commercially insured patients with chronic pain in 2014. Nearly one-fifth (19.0%) of 
1Included antidepressant medications were those from the tricyclic and serotonin/norepinephrine reuptake inhibitor (SNRI) classes; 
included anticonvulsant medications were gabapentin, pregabalin, carbamazepine, and oxcarbazepine.
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patients with chronic pain had a prescription for only a nonopioid. The use of only 
nonopioids was more common among patients aged 50–64 years and females. NSAIDs and 
antidepressants were the most commonly used nonopioids among patients with chronic pain. 
The common use of antidepressants among patients with chronic pain (12.2%, data not 
shown) compared to patients with no chronic pain (2.9%, data not shown) suggests that this 
class of drug likely is being used to treat conditions besides depressive disorders, or to 
potentially treat both chronic pain and a depressive disorder simultaneously.
This is the first study to examine the prevalence of nonopioid prescriptions among patients 
with chronic pain and more specifically the prevalence of prescriptions for both opioids and 
nonopioids. The CDC Guideline recommends nonopioid therapy, both pharmacologic and 
nonpharmacologic, as the preferred treatment for chronic pain outside of end of life, 
palliative, or active cancer care (6). The results of this study, using data that predate the CDC 
Guideline, provide a baseline profile of nonopioid prescriptions that can be tracked over time 
to examine the impact of the CDC Guideline and other evidence-based opioid prescribing 
guidelines on nonopioids prescriptions among patients with chronic pain.
This study has some limitations. First, although the sample is large, this study focuses on the 
commercially-insured population and it cannot be extrapolated to the entire U.S. population, 
those with public insurance, or the uninsured. Second, this study cannot fully differentiate 
between patients that take medication solely for chronic pain, for other conditions, or for 
multiple conditions. Third, the fill date of the prescription may be earlier than the chronic 
pain diagnosis, as prescription date cannot be linked to date of diagnosis in this database. 
Fourth, as chronic pain was identified by the presence of an ICD-9-CM code associated with 
chronic pain, patients experiencing chronic pain who were not assigned a chronic pain 
ICD-9-CM code would not be captured in this analysis. Fifth, while the list of medications 
used for this analysis is comprehensive, not all drugs used in off-label fashions to treat 
chronic pain may be captured here. Lastly, 38.3% of chronic pain patients did not receive 
either opioid or nonopioid prescriptions for pain. However, these patients may have utilized 
nonopioids obtained over the counter or other nonpharmacologic treatments such as physical 
therapy and acupuncture that are not captured in this data.
Conclusions
The prevalence of a prescription nonopioid among patients with chronic pain is higher than 
that for an opioid prescription. However, both opioid and nonopioid prescriptions are 
common. This suggests that prescribers are using a combination of opioids and nonopioids 
to treat chronic pain. Further research should analyze the impact of the CDC Guideline on 
nonopioid use and the timing of nonopioid and opioid prescribing among patients with 
chronic pain, as this study was not able to discern whether opioids were prescribed first or 
whether they were prescribed after nonopioids were not effective. Information onprescribing 
practices of nonopioids and opioids will aid in developing policies and practices to target 
populations most at risk for opioid misuse and overdose.
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Table 1:
Characteristics of all continuously-enrolled patients with commercial outpatient claims, by presence or 
absence of a chronic pain diagnosis - Marketscan, 2014
Demographic characteristics Chronic pain
diagnosisb
No chronic pain
diagnosis
Number of Patients 2,072,060 19,673,173
Diagnosis of a depressive disorder (%) 15.01 6.73
Diagnosis of a seizure disorder (%) 1.52 0.76
Age (mean (SD) (years)) 45.24 (13.78) 33.22 (18.80)
Age (years)a
   <18 5.84 27.00
   18–29 8.47 15.72
   30–39 14.74 14.16
   40–49 23.86 17.05
   50–64 47.09 26.07
Sex (%)a
   Male 38.30 46.10
   Female 61.70 53.90
Insurance plan typeac
   Comprehensive 2.61 1.84
   Exclusive Provider Organization (EPO) 0.97 1.11
   Health Maintenance Organization (HMO) 9.61 11.19
   Point of Service (POS) 6.05 5.60
   Preferred Provider Organization (PPO) 64.63 61.31
   Point of Service with capitation (POS/cap) 0.65 0.74
   Consumer Driven Health Plan (CDHP) 9.82 10.65
   High Deductible Health Plan (HDHP) 5.67 7.56
Regiona
   Northeast 21.15 20.67
   North Central 21.23 20.85
   South 38.90 38.96
   West 16.36 16.80
   Unknown 2.35 2.71
Prescription statusa
   No opioid or nonopioid prescriptions 38.33 74.63
   Opioids only 15.88 9.46
   Nonopioids onlyd 17.35 8.93
   Both opioids and nonopioidsd 28.44 6.97
aColumn percentages are presented
bAll comparisons between patients with or without chronic pain were statistically significant at the p<0.001 level.
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cComplete definitions for insurance plan type can be found from Truven Health MarketScan®Database7
d
Includes nonsteroidal anti-inflammatory drugs (NSAIDs), analgesics/antipyretics, anticonvulsants, and antidepressants.
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Table 2:
Prevalence of opioid and nonopioida prescriptions by demographic data among patients with chronic pain - 
Marketscan, 2014
Prescription Groupings
Demographic Characteristics
(n=2,072,060)
No opioid or
nonopioid
prescriptions
(n=794,242)
Opioids
only
(n=328,978)
Nonopioids
only
(n=359,536)
Both opioids
and
nonopioids
(n=589,304)
Diagnosis of a depressive disorder 21.91 14.25 18.97 44.88
Diagnosis of a seizure disorder 25.51 13.08 21.14 40.27
Age (years) b
   <18 69.48 9.56 13.49 7.47
   18–29 46.90 14.59 16.46 22.04
   30–39 41.45 15.72 15.89 26.94
   40–49 36.73 15.75 17.81 29.72
   50–64 32.77 17.01 18.22 32.01
Sexb
   Male 41.05 18.03 15.04 25.88
   Female 36.65 14.54 18.79 30.03
Insurance plan typebc
   Comprehensive 29.78 20.62 14.86 34.75
   Exclusive Provider
   Organization
43.59 14.48 17.80 24.14
   Health Maintenance
   Organization
34.55 15.57 19.76 30.13
   Point of Service 36.03 16.59 17.29 30.09
   Preferred Provider
   Organization
38.53 15.85 17.23 28.39
   Point of Service with capitation 32.90 16.62 18.58 31.90
   Consumer Driven Health
   Plan
37.95 15.65 17.38 29.01
   High Deductible Health
   Plan
45.60 15.25 16.15 22.99
Regionb
   Northeast 44.63 14.04 19.26 22.07
   North Central 39.91 16.29 16.02 27.78
   South 32.51 16.21 17.97 33.31
   West 42.89 16.93 14.90 25.28
   Unknown 32.01 15.72 19.09 33.18
aNonopioids refers to prescriptions for nonopioid pain reliever medications, including NSAIDs, analgesics/antipyretics, anticonvulsants, and 
antidepressants.
b
Row Percentages are presented
cComplete definitions for insurance plan type can be found from Truven Health MarketScan®Database7
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